Literature DB >> 18341528

Endogenous sex hormones and C-reactive protein in healthy postmenopausal women.

S Störk1, M L Bots, D E Grobbee, Y T van der Schouw.   

Abstract

BACKGROUND: Oral oestrogen replacement therapy increases levels of C-reactive protein (CRP). CRP is an established strong predictor of cardiovascular events. It is unknown whether endogenous oestrogen levels are associated with CRP. We therefore studied the relationship between endogenous sex hormones and CRP in healthy postmenopausal women emphasizing the role of body composition as peripheral fat is both a main source of oestrogen production after menopause and an endocrine tissue with inflammatory activities. SUBJECTS AND METHODS: The study population comprised 889 women participating in the PROSPECT study, an ongoing population-based cohort study. Information on risk factors was collected by questionnaires and clinical examination. Endogenous sex hormone levels and CRP were measured with double antibody radio immuno assay (RIA) from fasting plasma samples. In this cross-sectional study, associations between risk factors and lnCRP were studied using linear regression models.
RESULTS: Increases in oestrone and free oestradiol levels and the free androgen index were related to an increase in lnCRP of 1.19, 1.23 and 1.21 mg dL(-1) respectively. Body mass index (BMI), waist circumference and physical activity were strongly related to CRP levels, independent of age and other cardiovascular risk factors. Levels of all sex steroids but dehydroepiandrostenedione decreased with age. In age-adjusted analyses, an increase in waist circumference or BMI by one quartile was associated with a 1.28-fold and 1.26-fold increase in CRP. The relationship between endogenous hormones and CRP was modestly attenuated but remained highly significant after adjustment for body composition, physical activity and other traditional cardiovascular risk factors.
CONCLUSIONS: Our findings show that in postmenopausal women high levels of endogenous oestrogenic and androgenic sex steroids coincide with high CRP levels. This was only explained in part by markers of body composition or intra-abdominal fat.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18341528     DOI: 10.1111/j.1365-2796.2008.01946.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  12 in total

1.  Mammographic density change with 1 year of aerobic exercise among postmenopausal women: a randomized controlled trial.

Authors:  Christy G Woolcott; Kerry S Courneya; Norman F Boyd; Martin J Yaffe; Tim Terry; Anne McTiernan; Rollin Brant; Rachel Ballard-Barbash; Melinda L Irwin; Charlotte A Jones; Sony Brar; Kristin L Campbell; Margaret L McNeely; Kristina H Karvinen; Christine M Friedenreich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-23       Impact factor: 4.254

2.  Endogenous estradiol and inflammation biomarkers: potential interacting mechanisms of obesity-related disease.

Authors:  Ronald C Eldridge; Nicolas Wentzensen; Ruth M Pfeiffer; Louise A Brinton; Patricia Hartge; Chantal Guillemette; Troy J Kemp; Ligia A Pinto; Britton Trabert
Journal:  Cancer Causes Control       Date:  2020-02-25       Impact factor: 2.506

3.  Inflammatory markers and the risk of hip fracture: the Women's Health Initiative.

Authors:  Kamil E Barbour; Robert Boudreau; Michelle E Danielson; Ada O Youk; Jean Wactawski-Wende; Nancy C Greep; Andrea Z LaCroix; Rebecca D Jackson; Robert B Wallace; Douglas C Bauer; Matthew A Allison; Jane A Cauley
Journal:  J Bone Miner Res       Date:  2012-05       Impact factor: 6.741

4.  SHBG, sex hormones, and inflammatory markers in older women.

Authors:  Marcello Maggio; Gian Paolo Ceda; Fulvio Lauretani; Stefania Bandinelli; Anna Maria Corsi; Francesco Giallauria; Jack M Guralnik; Giovanni Zuliani; Chiara Cattabiani; Stefano Parrino; Fabrizio Ablondi; Elisabetta Dall'aglio; Graziano Ceresini; Shehzad Basaria; Luigi Ferrucci
Journal:  J Clin Endocrinol Metab       Date:  2011-01-14       Impact factor: 5.958

5.  Endogenous hormones and coronary heart disease in postmenopausal women.

Authors:  Yu Chen; Anne Zeleniuch-Jacquotte; Alan A Arslan; Oktawia Wojcik; Paolo Toniolo; Roy E Shore; Mortimer Levitz; Karen L Koenig
Journal:  Atherosclerosis       Date:  2011-03-01       Impact factor: 5.162

6.  Endogenous sex hormones and their associations with cardiovascular risk factors in post-menopausal women.

Authors:  N Güdücü; U Görmüş; S S Kutay; Z N Kavak; B Telatar
Journal:  J Endocrinol Invest       Date:  2013-02-27       Impact factor: 4.256

7.  Polycyclic aromatic hydrocarbon biomarkers and serum markers of inflammation. A positive association that is more evident in men.

Authors:  Omayma Alshaarawy; Motao Zhu; Alan Ducatman; Baqiyyah Conway; Michael E Andrew
Journal:  Environ Res       Date:  2013-08-22       Impact factor: 6.498

8.  Associations of PCBS, dioxins and furans with follicle-stimulating hormone and luteinizing hormone in postmenopausal women: National Health and Nutrition Examination Survey 1999-2002.

Authors:  Anissa Lambertino; Victoria Persky; Sally Freels; Henry Anderson; Terry Unterman; Saria Awadalla; Mary Turyk
Journal:  Chemosphere       Date:  2020-09-11       Impact factor: 7.086

9.  Chronic residential exposure to particulate matter air pollution and systemic inflammatory markers.

Authors:  Barbara Hoffmann; Susanne Moebus; Nico Dragano; Andreas Stang; Stefan Möhlenkamp; Axel Schmermund; Michael Memmesheimer; Martina Bröcker-Preuss; Klaus Mann; Raimund Erbel; Karl-Heinz Jöckel
Journal:  Environ Health Perspect       Date:  2009-05-11       Impact factor: 9.031

10.  High level of plasma estradiol as a new predictor of ischemic arterial disease in older postmenopausal women: the three-city cohort study.

Authors:  Valérie Scarabin-Carré; Marianne Canonico; Sylvie Brailly-Tabard; Séverine Trabado; Pierre Ducimetière; Maurice Giroud; Joanne Ryan; Catherine Helmer; Geneviève Plu-Bureau; Anne Guiochon-Mantel; Pierre-Yves Scarabin
Journal:  J Am Heart Assoc       Date:  2012-06-22       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.